Preventive healthcare startup Lucis has raised $20 million in Series A funding led by Singular, with participation from General Catalyst, Y Combinator, and several angel investors including backers of Runna.
The funding comes only four months after the company’s $8 million seed round, bringing total funding raised to $28 million.
Building A Data-Driven Preventive Healthcare Platform
Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis is developing a preventive health platform designed to help individuals monitor and improve long-term health before symptoms or disease emerge.
The platform analyses more than 110 blood biomarkers across key health categories including metabolic function, cardiovascular risk, inflammation, hormone balance, and nutrient levels.
Users receive results through an AI-powered health companion app that combines biomarker analysis, longitudinal health tracking, and medical context to generate personalised recommendations covering nutrition, supplements, lifestyle changes, and follow-up testing.
Recommendations evolve continuously as new health data is added, while physician review provides an additional layer of clinical oversight.
Advertisement
Strong Early User Adoption And Engagement
Lucis says early user data indicates high engagement and measurable improvements in health outcomes.
Among users who completed six-month follow-up testing, 75% improved at least three biomarkers without medication, while more than 80% continued monitoring through repeat testing.
The company also reports that nearly all users initially discovered at least one biomarker outside optimal ranges, highlighting the broader need for more proactive and continuous health monitoring.
Since launching in 2025, Lucis has grown to more than 10,000 users across France, the UK, Ireland, and Portugal, processing over one million biomarker tests.
Expanding Across Europe
Lucis currently operates with a team of 20 spanning engineering, product, clinical operations, and growth, supported by a medical board and physician network.
The company has also partnered with laboratory providers including Eurofins and Randox.
The new funding will support expansion into Spain, Germany, and Italy by the end of 2026, while accelerating investment in personalisation, longitudinal health tracking, and clinical safety systems.
“We’ve seen firsthand the consequences of late-stage diagnosis,” said co-founder and CEO Maxime Berthelot.
“The science already exists. What’s missing is a healthcare system designed to act before symptoms appear. Our goal is to make prevention the default rather than a privilege.”
About Lucis
Lucis is a preventive healthcare company building an AI-powered biomarker analysis and health monitoring platform. The company combines blood testing, longitudinal tracking, and personalised clinical insights to help users proactively manage long-term health and reduce the risk of chronic disease.
